Should Psychedelic Therapists Be Required To Take Psychedelics? TheraPsil Training Advisor Dave Phillips Weighs In
Last reviewed and updated: July 3, 2026.
Key Takeaways
| Oregon licensing | Competency-based; personal experience NOT required; most training programs strongly recommend it but don’t mandate it; 160+ hr approved training is the legal standard |
| MAPS approach | Original MDMA-AT training included personal session; under revision post-2024 FDA rejection; personal experience may introduce functional unblinding confound that complicates research regulatory pathway |
| The empirical question | No controlled studies comparing facilitators with vs. without personal experience; Oregon cohort is now positioned to generate this data; early observational data is inconclusive but cuts against the strong “required” position |
| Training alternatives | Deep somatic (sensorimotor psychotherapy, SE), IFS, and trauma-informed approaches appear to produce equivalent or better facilitation skills in some practitioners, independent of personal experience |
| Patient preference | Many patients prefer facilitators with personal experience; this preference is clinically relevant but may reflect training quality as a proxy rather than a direct causal effect of the experience itself |
If psychedelics were legalized tomorrow, would the healthcare system be ready for psychedelic-assisted therapies? While there are plenty of biotech companies eager to supply drugs like psilocybin and MDMA for therapeutic use, psychedelic-assisted therapies won’t be accessible until enough therapists and practitioners have undergone the appropriate training. That training usually involves undergoing psychedelic-assisted therapy themselves.
Enter TheraPsil, a non-profit coalition that has helped dozens of Canadians in medical need access psilocybin-assisted therapy legally.
In addition to helping patients, TheraPsil offers an intensive training program for healthcare professionals who want to learn the necessary skills to work with psilocybin in a therapeutic context. To date, more than 220 therapists, doctors, nurses, and counselors have successfully completed TheraPsil’s training program, the first legal therapeutic psilocybin training course in the country.
Dave Phillips, TheraPsil’s training advisor, has worked as a registered clinical counsellor since 1992 and began working with psychedelics in 2017. He recently sat down with Healing Maps to discuss his work and unpack some of the key concepts taught in TheraPsil’s training program.
RELATED: The Stigma Of Psychedelics – Why ‘Illegal’ Doesn’t Always Mean ‘Dangerous’
Healing Maps (HM): What inspired you to start working with psychedelic medicines in a therapeutic context?
Dave Phillips (DP): “I’ve been a therapist for a long time, and I’ve been trauma-informed my whole career. I really do try to do my best work for people, but in 2015, I was really seeing how, even if people worked really hard, and we met regularly for two or three years, we could only get to a certain point. It was frustrating, and at one point, I even thought about giving up my career because of it.
“Then I read an article about MAPS, which I’d never heard of before, and it talked about how they were treating PTSD with MDMA. I remember thinking, ‘I don’t buy it,’ but that was the first time I was exposed to the idea of using medicines in therapy.
“Six months later, I read about Johns Hopkins using psilocybin for end-of-life anxiety. I didn’t know what psilocybin was, but that got my attention because of Johns Hopkins’ reputation. That got me into the research, and for two years, I dug into everything I could before I said, ‘I want to be a psychedelic therapist.’ What was really clear was, if I was going to be a psychedelic therapist, I had to try psilocybin myself. That led me to have my own psilocybin experience, and everything changed after that.”
HM: You’ve said that your experience with magic mushrooms helped make you a more empathetic psychotherapist. Do you think it’s necessary that therapists have their own psychedelic experiences before working with other people?
DP: “One hundred percent. For me, it’s an issue of safety. Because it involves such an altered state, I think practitioners really do have to have first-hand experience of the territory. Having that understanding of what the space is like helps you move more fluidly.
“The mistake most new psychedelic therapists make is they over-function — they try and get in and do something in the trip, when really what you want to do is keep the trip moving. You may have to intervene occasionally, but for the most part, you just want to hold the space and stay connected. The subtleties of that are forged in the experience of your own journey. At TheraPsil, that’s an absolute boundary.”
RELATED: 3 Great Books About Psychedelics For Integrating Your Psychedelic Experience
HM: You’ve said, “there are no bad trips, only challenging ones.” What do you mean by that?
DP: “Most people define a bad trip as losing your agency; as in, something is happening that you feel you can’t control and you don’t like it, and it can often also be overwhelming or terrifying. That can happen sometimes in therapeutic settings, and we can’t mitigate that, but the client is supported through this experience by the therapist. What makes a bad trip in my judgement, is that you are alone: you’re in the middle of chaos, perhaps you don’t know where you are, you might be what we describe as ‘freaking out.’ That can be traumatizing, and you can get PTSD from that kind of experience.
“In a therapeutic setting, I’m not saying that you can’t have a hard or challenging trip, but because you’re connected to people that can keep you safe, it’s not the same kind of negative experience. I believe we can all have challenging trips, but there are no bad trips.”
HM: What are some of the key concepts you teach to students in training?
DP: “Everything that we learn in the course and everything that informs our decisions is taught through the lens of safety and efficacy. Patient safety is the most important consideration because it’s a very vulnerable state when people take the equivalent of five grams of mushrooms.
“We have to mitigate any risk to them, as much as possible, and that’s a big part of our training. We discuss important things like preparation, intentions, and set and setting, but at the same time, we also talk about agency. It’s important that at every step of the way, we’ve done as good a job as we can of explaining things, so that consent is fully informed. We can’t tell people what the experience will be like because it’s always unique to the individual, but we can explain to them the sorts of things that can happen, and what we will do if there are tough moments.
“Every client, especially clients for psychedelic therapy, has the right to feel prized by their therapist. In order for me to prize someone, I have to have a lens through which I can understand them, and in the course, that lens is trauma-informed. In my judgment, for almost every client, the core issue is trauma. You’ve got to really feel like it’s a privilege to be working with this person.
“Oftentimes, people are pretty desperate if they are choosing psychedelic therapy — they’ve tried everything, and it hasn’t worked. When we have great compassion and understanding for them, it allows them to trust us, and that can lead to more positive outcomes in the sessions.”
This interview has been edited for clarity and length.
The Personal Experience Debate in 2025–2026: From Theory to Practice
When this debate was first captured here, it was largely theoretical — discussed in training program curricula, psychedelic therapy forums, and practitioner conferences, but not yet tested against real-world licensing frameworks with real-world outcomes data. That has changed. Oregon’s licensed psilocybin facilitator program has now produced a cohort of licensed facilitators across different background profiles; MAPS’s MDMA-assisted therapy program ran a training that included personal experience as a component before the 2024 FDA rejection paused it; and early observational data from Oregon’s service centers is beginning to surface. The debate is now being tested empirically rather than adjudicated purely philosophically, and the early picture is genuinely more complex than either side of the argument anticipated.
Oregon’s licensing approach: competency-based, not experience-based. Oregon’s licensed psilocybin facilitator program — the only active domestic licensing framework for this work — does not require personal psilocybin experience as a condition of licensure. The Oregon framework is competency-based: facilitators must complete an approved training program (minimum 160 hours), demonstrate specific facilitation skills, pass a written examination, and meet character and fitness standards. Personal experience with psilocybin is neither required nor prohibited as part of Oregon licensing. Most Oregon-approved training programs — Fluence, InnerTrek, and others — do incorporate personal experience as a training component, but this varies by program, and completion of a personal session during training is still not a legal requirement for licensure. It is worth noting that the training programs that most strongly recommend personal experience are typically led by practitioners who came up through clinical trial or underground facilitation backgrounds, where personal experience was assumed to be part of the preparation. Whether that recommendation reflects clinical evidence about facilitator effectiveness or reflects a cultural norm being formalized is precisely the empirical question the Oregon cohort will help answer.
MAPS’s approach, pre-2024 rejection: personal experience was included. MAPS’s MDMA-assisted psychotherapy training program — which produced a cohort of therapists who participated in the Phase 3 trials — did include a personal MDMA session component in its original protocol. The rationale was explicit: MAPS leadership believed that therapists who had experienced MDMA’s effects firsthand would be better equipped to hold the therapeutic space for patients, would be more calibrated in their response to the intensity of the experience, and would have greater therapeutic empathy for the state they were facilitating. Following the FDA’s August 2024 rejection of MDMA-assisted therapy (citing methodological concerns about unblinding and functional unblinding bias), MAPS’s clinical program was substantially restructured. The role of personal therapist experience in the revised protocols being developed for resubmission is not yet publicly specified. The FDA’s concern about unblinding bias is actually relevant here: therapists who have personal MDMA experience may have been more likely to correctly guess which patients received active drug, which the FDA cited as a methodological problem. This creates a somewhat ironic tension: personal experience may improve therapeutic quality but also introduce a specific research confound that the regulatory pathway finds problematic.
The empirical question remains open — and some early data cuts against the strong version of the “experience required” argument. Among the early Oregon licensed facilitator cohort, some of the most consistently well-reviewed practitioners — based on the limited observational and client feedback data emerging from service centers — come from psychotherapy backgrounds (somatic therapy, IFS, trauma-informed CBT) without personal psilocybin experience. Their facilitation effectiveness appears to draw from depth of therapeutic presence, trauma training, and somatic attunement rather than from experiential familiarity with the specific state. This is an observational finding from a small early cohort, not a controlled study — but it is consistent with the theoretical argument that what facilitators bring to the container is primarily relational and therapeutic skill, not experiential memory. The patient preference data cuts the other direction: many patients report feeling greater trust with facilitators who have had personal experience, and this preference is real and clinically relevant. The most honest summary of the current state: personal experience appears to be one pathway to good facilitation, not the only pathway; and neither requiring it nor prohibiting it as a licensing condition is currently supported by controlled evidence. The Oregon psilocybin services community is actively debating this, and it will remain an open professional question for years.
Frequently Asked Questions
Do psychedelic therapists need to have taken psychedelics themselves?
Currently, no — not as a legal requirement. Oregon’s licensed psilocybin facilitator program, the only active domestic licensing framework, is competency-based and does not require personal psilocybin experience for licensure. Most approved training programs include personal experience as a recommended or included component of training, but it remains optional as a legal matter. The professional debate about whether personal experience should be required is active and unresolved. The strongest argument for requiring it is that having navigated a significant psychedelic state oneself produces a calibration of response — a felt sense of the intensity, the progression, the moments of challenge and integration — that is difficult to fully convey through didactic training alone. The strongest argument against requiring it is that effective facilitation is primarily a function of therapeutic skill, relational capacity, and trauma training, not experiential memory of a specific state; and that some of the most consistently effective facilitators in Oregon’s early cohort have psychotherapy backgrounds without personal psychedelic experience. Neither position is currently backed by controlled outcome data comparing facilitators with and without personal experience. This will be one of the important empirical questions that Oregon’s licensed framework generates data on in the coming years.
What training do licensed psilocybin facilitators in Oregon complete?
Oregon-licensed psilocybin facilitators must complete a state-approved training program of at least 160 hours. These programs cover: the pharmacology and neurochemistry of psilocybin; preparation session skills (how to build therapeutic alliance, identify contraindications, and set intentions with clients); facilitation skills during the session (how to be present without being intrusive, how to support difficult experiences, when and how to intervene); integration support (how to help clients make meaning and apply insights post-session); safety protocols and emergency procedures; cultural competency and equity considerations; and Oregon’s specific legal and regulatory framework. After completing approved training, facilitators must pass a written examination and meet character and fitness standards. Oregon-approved training programs as of 2026 include InnerTrek, Fluence, the Psychedelic Research and Training Institute (PRATI), and several others. Programs vary in how they incorporate personal experience: some include a supervised psilocybin session during training; others strongly recommend it but do not require it; a few leave it entirely to the trainee. The specific content of individual training programs is publicly available through the Oregon Health Authority’s approved training program registry.
What is the argument against requiring personal psychedelic experience?
Several distinct arguments have been made against making personal psychedelic experience a mandatory requirement for facilitator licensure. The strongest empirical argument is that effective facilitation appears to be primarily a function of therapeutic presence, relational skill, trauma training, and somatic attunement — capacities that can be developed through rigorous clinical training without personal drug experience, and that some practitioners develop to a high level through exactly that path. Early observational data from Oregon’s first licensed facilitator cohort includes well-regarded practitioners without personal experience whose effectiveness draws from IFS, somatic therapy, and trauma-informed approaches. A second argument involves equity and access: requiring personal experience with an illegal substance creates legal and safety risks for aspiring facilitators in states and jurisdictions where psilocybin remains prohibited, and may create barriers for practitioners from communities where drug use carries particular stigma or risk. A third argument, relevant specifically to the FDA research pathway, is that therapist personal experience may introduce a research confound (functional unblinding) that complicates regulatory approval pathways — a concern that played into the MAPS MDMA-AT rejection. The counterarguments are also real: patient preference for experienced facilitators is a clinical consideration; and the felt sense of having navigated a significant non-ordinary state may produce capacities that are genuinely difficult to replicate through other means. The debate will be most usefully resolved by outcome data comparing facilitators across experience profiles, which Oregon is now positioned to generate.
How do I find a well-trained psychedelic therapist?
The most reliable starting point for finding a well-trained psychedelic therapist or facilitator is the Oregon Health Authority’s public registry of licensed psilocybin service centers and licensed facilitators — this is the only category of provider in the US with state-verified training and licensure for psilocybin work. For therapy that incorporates psychedelic integration (working through a prior psychedelic experience with a therapist, without administering a substance in session), look for therapists who have completed recognized psychedelic therapy training programs: Fluence, MAPS training alumni, CIIS (California Institute of Integral Studies) certificate programs, and Naropa University programs are among the most established US-based credentials. The Multidisciplinary Association for Psychedelic Studies (MAPS), the Psychedelic Medicine Association, and the Psychedelic Support therapist directory all maintain provider directories that can be useful starting points. When evaluating any provider, the questions that most predictably differentiate effective from ineffective practitioners are: What is your specific training in psychedelic facilitation or integration (not just general psychotherapy)? How do you structure preparation sessions? What integration support do you provide after a session? Have you worked with patients whose experiences were difficult or distressing, and how do you handle that? A well-trained practitioner should have clear, thoughtful answers to each of these — and should be comfortable not having personal experience if that is their situation, without being defensive about it.
